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Disability Index. Data at screening and baseline were used to
examine the convergent validity, discriminant validity, internal
consistency, and test-retest reliability. Convergent validity was
tested, using Pearson’s correlations, by comparing total and sub-
scale scores on the CSHQ-RA to those from the Mental and
Physical Component Summary (MCS and PCS) of the MOS SF-
36 and HAQ. ANOVA and Kruskal-Wallis tests were used to
assess the discriminant validity of the CSHQ-RA. Internal 
consistency was measured by Cronbach’s alpha coefﬁcient.
Test–retest reliability was assessed using intraclass correlation
coefﬁcients (ICCs). RESULTS: Response rate at baseline was
95% (291). Eighty-one percent of respondents were female;
mean age was 52 years (± 12); mean duration with RA was 10.8
years (± 10.4). At baseline, mean scores on instruments were
HAQ 1.5 (± 0.7), MCS 37.9 (± 10.9), and PCS 31.2 (± 8.3).
Pearson’s correlations between the CSHQ-RA and the MOS SF-
36 and HAQ scores ranged from -0.33 to -0.73 (P < 0.0001)
and 0.39 to 0.76 (P < 0.0001), respectively. The difference in
scores on the CSHQ-RA of patients with different levels of phys-
ical disability as measured by the HAQ was statistically signiﬁ-
cant (P < 0.0001). Cronbach’s alpha coefﬁcients were ≥0.9
indicating good internal consistency. Test-retest reliability was
demonstrated in the instrument’s subscales with ICCs ranging
from 0.82 to 0.94. CONCLUSIONS: These results support the
validity and reliability of the original CSHQ-RA when tested in
a representative patient population. Research to assess respon-
siveness and clinically signiﬁcant change of the CSHQ-RA is
underway.
AR4
THE DEVELOPMENT OF PROPENSITY SCORES FROM
ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE
EFFECTIVENESS OF AN OSTEOARTHRITIS ACADEMIC
DETAILING SERVICE ON PRESCRIBING BEHAVIOUR
Graham SD, Hartzema AG
University of Florida, Gainesville, FL, USA
OBJECTIVES: The Nova Scotia Osteoarthritis (OA) Academic
Detailing Service is voluntary and as such questions of selection
bias when comparing the physicians’ prescribing behaviour that
volunteered with those that did not are justiﬁed. The objective
is to abate this bias, using propensity score methodology to
create balanced experimental groups for the analysis of pre-
scribing behaviour. METHODS: A total of 989 of the 1403
general practicioners in Nova Scotia met the inclusion criteria
for the study (312 received the OA service, 677 did not). The
propensity score for each physician was calculated using a logis-
tic regression analysis; with participation in the OA service as
the dependent variable and 10 independent variables that
described the physician’s personal and practice characteristics.
RESULTS: The 10 independent variables were tested for signif-
icant differences (alpha = 0.05, t-test for continuous and chi-sq
for catagorical variables) before and after the propensity analy-
sis was conducted. Nine of the 10 variables showed signiﬁcant
difference between the experimental groups in the pre-
propensity comparison whereas only 1 variable showed a sig-
niﬁcant difference in the post-propensity comparison. CON-
CLUSIONS: The propensity score methodology was successful
in abating selection bias by eliminating signiﬁcant differences
between variables measuring physician characteristics. It also
identiﬁed one variable (participation in a previous inﬂuenza
detailing service), which remained a signiﬁcant predictor of 
participation in the OA service after the propensity score was
completed (pre-propensity chisq = 407.48, p < 0.0001 and 
post-propensity chisq = 15.46, p < 0.0001). As such, there is a
strong argument that this variable should be included as a covari-
ate in the statistical analysis of behavioural differences between
the groups.
SESSION II
HEALTH CARE REIMBURSEMENT
HR1
DO DRUG PRICES REFLECT VALUE? DO FORMULARY
POLICIES?
Neumann PJ, Lin PJ, Rosen AB, Greenberg D, Olchanski NV,
Weinstein MC
Harvard School of Public Health, Boston, MA, USA
OBJECTIVES: Prescription drugs that provide high value should
command higher prices than lower value drugs other things
equal. We examined correlations between a drug’s price and its
economic merit, as measured in cost-utility analysis (CUAs). We
also examined whether formularies policies are consistent with
cost-utility (CU) ratios. METHODS: CUAs from 1998 through
2001 on pharmacotherapies were selected from a large registry
of analyses. All CU ratios and drug cost estimates were taken as
reported in analyses and standardized to 2002 US$. Spearman
correlation coefﬁcients were used to quantify the association
between drug prices and CU ratios. We examined the Florida
Medicaid Preferred Drug List and Harvard Pilgrim Pharmacy
Program to analyze whether insurers cover drugs with good
value. Wilcoxon rank sum test was performed to assess if pre-
ferred drugs had different ratios than non-preferred drugs.
RESULTS: Of 205 ratios, 16.1% were for short-term treatment
(<2 months), 29.8% intermediate treatment (2–18 months), and
54.2% lifetime treatment. Ten and seven-tenths percent of ratios
were cost saving and 8.3% dominated. Correlations between
ratios and prices were 0.4991 (p = 0.0069), 0.1154 (p = 0.4724)
and 0.2892 (p = 0.0041) for short, intermediate, and lifelong
drugs, respectively. CU ratios did not differ signiﬁcantly from
preferred to non-preferred drugs on both health plans. Among
cost-saving therapies, only 68.2% were covered by Florida Med-
icaid and 72.7% by Harvard Pilgrim. Among dominated drug
interventions, 88.2% were covered by Florida Medicaid and
94.12% by Harvard Pilgrim. CONCLUSIONS: CU ratios of
pharmacotherapies are positively associated with price, but the
correlation is low among intermediate and lifelong treatments.
Preferred drugs on two health plans generally do not reﬂect
better cost-effectiveness. These results may reﬂect the absence of
value-based pricing and lack of evidence-based reimbursement
policies, or the fact that CUAs are poorly conducted (e.g., they
have inappropriate comparators), or do not reﬂect decision
makers’ perceptions of value.
HR2
DECISION-MAKER’S PERCEPTIONS OF ACCESS TO HIGH
COST DRUGS (HCDS) IN PUBLIC HOSPITALS IN AUSTRALIA
Gallego G,Taylor S, Brien JAE
The University of Sydney, Sydney, NSW, Australia
OBJECTIVE: To investigate the perceptions, concerns and atti-
tudes of decision-makers regarding access to HCDs in public
hospitals. METHODS: In-depth, semi-structured interviews
were conducted with public hospital senior managers, directors
of pharmacy and senior medical doctors in a Sydney Area Health
Service. Topics for the interviews included the decision-making
process and associated problems and solutions to matters of
access to HCDs. Interviews were audiotaped, transcribed verba-
tim, thematically content analyzed and coded using NVivo soft-
ware. RESULTS: Data analysis identiﬁed a number of emerging
themes. Decision-makers perceived health care system funding
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models as obstacles to equity of access to HCDs. They were con-
cerned that there were inequities in decisions for individual
patients depending on public or private sector hospital status.
Tertiary public hospitals were perceived to be at the ‘cutting
edge’ and therefore were required to fund new, expensive drugs.
A major concern for respondents was that, as a consequence, this
meant prioritizing between patient groups and individual cases.
“Why is one patient group more important than another patient
group and how do we decide which drugs should be available
to each patient?” The majority of respondents identiﬁed equity
problems in access to HCDs, however they had difﬁculty in iden-
tifying solutions. Respondents described that, besides safety,
effectiveness, efﬁcacy and cost, ethical principles should be borne
in mind when deciding whether a HCD should be available in a
public hospital. Most wanted a transparent, accountable, evi-
dence-based decision-making process. CONCLUSION: The pre-
liminary results of this study suggest that decision-makers were
concerned about the equity of access to HCDs in public hospi-
tals. They were concerned regarding the process for decision-
making and the outcomes of these decisions. Further research
will explore the views of the public regarding funded access to
HCDs.
HR3
COMPARISON OF REIMBURSEMENT SYSTEMS OF VARIOUS
COUNTRIES IN CENTRAL AND EASTERN EUROPE,AFRICA,
AND MIDDLE EAST
Davey P, Lees M, Makino K, Price N, Birinyi-Strachan L
M-TAG Pty Ltd, Chatswood, NSW, Australia
AIM: To perform a comparative examination of the drug reim-
bursement systems in 16 secondary markets in Central and
Eastern Europe, Africa, and Middle East. METHODS: The
results of this study are derived from published literature and
through interviews with key opinion leaders and reimbursement
ofﬁcials in each of the 16 countries. The reimbursement system
in each country is assessed by using a set of predeﬁned criteria.
Speciﬁcally, the criteria aim to investigate whether there is public
reimbursement of pharmaceuticals in the country, to identify
whether a formalised review process for reimbursement applica-
tion exists, whether or not a pharmacoeconomic evaluation is
required in the reimbursement application, and to determine if
a reference pricing system is implemented in price determination
for new pharmaceuticals. These criteria will allow an under-
standing of the types of reimbursement systems in these 
countries and identiﬁes trends in drug reimbursement policy.
RESULTS: A majority of the countries considered in this study
had some form of public reimbursement system for pharmaceu-
ticals. Notable exceptions include middle-eastern countries
where reimbursement is restricted to inpatients, while private
health insurance is more prevalent in countries like South Africa
and Russia. Very few countries, however, have an established
formal reviewing system for reimbursement applications. Refer-
ence pricing was common in these markets. Several countries are
in the process of introducing formal pharmacoeconomic require-
ments. CONCLUSION: The main concern of reimbursement
authorities in these countries is containment of increasing drug
costs. Several countries are increasingly formalizing this process.
HR4
IMPACT OF MEMBER COST-SHARING LEVELS ON
POPULATION-BASED STATIN USE RATES
Moore JM, Xiao JQ, Marks A
Caremark, Inc, Northbrook, IL, USA
OBJECTIVE: Numerous studies have found that substantial
increases in drug co-payments result in reductions in utilization
and spending. A recent study found that signiﬁcantly more
members faced with substantially increased costs stopped statin
therapy than a control group. High co-payments can inﬂuence
the decision to start needed drug therapy as well as to discon-
tinue it. This study analyzes population-based statin use rates as
one way to look at the impact of high cost sharing on the deci-
sion to start therapy as well as to continue statin therapy.
METHODS: The study included 15,937 statin users in 16
employer groups with average member cost share greater than
30% (HIGH) and 86,605 statin users in 48 employer groups
with member share less than 15%. Employer groups with DAW
penalties were excluded. LOW and HIGH share groups both had
retail and mail coverage. Drug utilization and group eligibility
data for 2003 came from Caremark Rx claims data system.
HIGH and LOW groups were compared on age and gender. Age-
speciﬁc population use rates were computed for 12 ﬁve-year age
bands between 30 and 89. RESULTS: Age-speciﬁc population-
based use rates for the HIGH share group averaged only 79%
of the level of the LOW share group. For example, the statin use
rate for 60–64 years of age was 279.1 per 1000 for the HIGH
share group and 359.8 per 1000 for the LOW share group.
CONCLUSIONS: High levels of member cost sharing impact
population-based statin use rates. Additional educational efforts
may be necessary to encourage use of preventive health care 
as members assume greater responsibility for the costs of 
medication.
HEALTH CARE COST EVALUATION
CE1
A FRAMEWORK FOR COSTING RECOMMENDATIONS IN
PHARMACOECONOMIC GUIDELINES
Jacobs P1, Brady BK2
1University of Alberta, Edmonton, AB, Canada; 2Canadian
Coordinating Ofﬁce for Health Technology Assessment, Ottawa, ON,
Canada
OBJECTIVE: Since 1992, pharmacoeconomic guidelines, which
contain speciﬁc costing recommendations, have been available
yet reviews of recent economic evaluations indicate that investi-
gators are still using a wide range of methods. This discourages
uniformity of results. Two possible reasons for this are 1) insuf-
ﬁcient detail in the recommended guidelines and 2) a lack of stan-
dardization. We conducted a comparative review of national
costing guidelines to determine the degree of detail provided 
in the guidelines and the degree of correspondence. The main
purpose was to develop a more comprehensive framework.
METHODS: Guidelines were identiﬁed and reviewed. A frame-
work with categories were developed, and all guidelines were
reviewed in light of these categories. RESULTS: Our framework
contained the following headings: General items, Resource iden-
tiﬁcation and classiﬁcation, Resource measurement, Resource
Valuation, and reporting cost per patient. Our review of guide-
lines indicated that major differences arose because of different
study purposes (studies conducted for formal formulary submis-
sions versus general purpose studies). Other differences between
the stated guidelines resulted from analytical differences in
costing analysis, in areas such as lifetime unrelated costs and lost
productivity costs. We also found an absence of detail in the
costing recommendations. CONCLUSIONS: Both with regard
to resource measurement and resource valuation categories, very
little conceptual guidance relating to the basic cost measure was
provided, and no systematic recommendations emerged with
regard to inter-temporal and geographical adjustments to the
basic cost measure. A more detailed set of recommendations is
proposed.
